Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
This article does not provide medical advice regarding supplement choices during travel.
The challenge is knowing how to recognize them
With growing evidence and expanding clinical use, GLP-1 therapies are reshaping treatment strategies
Peptide in Berlin Berliner Forschungsstandort, EU-Bezugsquellen, HPLC- und COA-Anforderungen sowie Schengen-Versand nach Berlin
J.et al (2014)
Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
US$ 27.68
US$ 28.64
US$ 25.32
US$ 28.55
US$ 20.19
